ACKNOWLEDGMENTS

The Editorial Board of Clinical Science gratefully acknowledges the assistance given by the following referees during the year 1995.

Abernathy, D.
Agardh, E.
Agrotis, A.
Aitkenhead, A.R.
Ali, N.
Andersen, D.
Anderson, S.
Andrews, F.
Angelin, B.
Araki, S.
Archard, L.
Ardawi, M.S.M.
Arieff, A.I.
Armstrong, V.W.
Arnold, J.M.O.
Amqvist, H.
Arslanian, S.
Arthur, J.
Astarie Dequecker, C.
Bailey, R.R.
Baines, A.
Bankir, L.
Banks, R.
Barclay, R.
Baron, A.D.
Barradas, M.A.
Barrett, E.J.
Barton, H.
Bassie, J.E.
Batchelard, H.
Beaudouin-Legros, M.
Beavan, L.
Beckett, G.
Bell, J.
Belpaire, F.
Benjamin, N.
Bennett, A.
Berl, T.
Berner, C.
Besley, G.
Best, J.
Beynon, H.
Bharaj, H.S.
Bhatnagar, D.
Bie, P.
Bishop, J.
Bistrian, B.R.
Black, C.
Blomberg, P.
Bobik, A.
Boer, W.H.
Bolter, C.P.
Bonham, J.
Bolton, C.
Boot-Handford, R.
Boughton-Smith, N.K.
Boulanger, C.
Bowyer, D.E.
Brain, S.D.
Brands, M.
Brasseur, D.
Bray, M.D.
Bray, S.W.
Bray, S.
Bright, R.
Briggs, G.
Brinton, K.E.
Brodie, D.
Brown, N.
Breyer, M.D.
Bringhurst, F.R.
Brodin, K.
Brodin, R.
Brooke, J.
Brown, M.
Bruce, H.
Bruns, J.
Bruno, G.
Bucalossi, J.
Buckley, A.
Buchanan, C.
Bucy, P.
Bulman, C.
Bull, D.
Bundy, M.
Burdon, S.
Burke, K.
Burden, R.H.
Burgess, A.W.
Burrell, L.M.
Burton, D.
Bussel, B.
Butler, J.
Butterworth, J.
Buyse, M.
Buzby, R.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
C.
L'Abbate, A.
Lacolley, P.
Lang, C.C.
Langley-Evans, S.C.
Lassen, N.A.
Laszlo, G.
Laurent, S.
Lazarus, J.H.
Lean, M.E.J.
Ledet, T.
Lennox, G.
Leonard, R.C.F.
Le Quan Sang, K.-H.
Lerman A.
Lipworth, B.J.
Lockwood, M.
Lombard, M.
Lombardi, F.
London, G.
Lowe, G.D.O.
Luke, R.
Lundholm, K.
Lyall, F.
Lydyard, P.M.
Macallan, D.
MacAllister, R.
Macdonald, I.A.
Macdonald, P.
MacFadyen, R.J.
MacNee, W.
Maggs, D.
Maling, T.J.B.
Malluche, H.
Manheim, K.
Mann, S.
Matthias, C.J.
Maxwell, S.R.J.
McClinton, S.
McConnell, A.K.
McGrath, B.
McGuinness, O.
McIntosh, R.S.
McLaughlin, P.J.
McLay, J.S.
McLindon, J.P.
McNally, P.
Meneilly, G.S.
Mihailidis, D.
Millar, J.A.
Miller, J.P.
Millward, D.J.
Mirman, A.
Mohanty, P.K.
Mol, M.J.
Moore, G.
Moore, K.
Morgan, M.Y.
Morris, C.
Morris, J.
Morrison, J.
Motwani, J.G.
Naismith, D.J.
Navi, G.J.
Neary, R.H.
Nemer, M.
Nestel, P.
Newham, D.J.
Newton, G.
Ng, L.L.
Nicholls, M.G.
Nilsson, H.
Niset, H.
Norman, R.I.
Novak, V.
Nussberger, J.
O'Brien, E.
O'Callaghan, C.
O'Connor, B.
Ohanian, J.
Olsen, N.V.
O'Morain, C.A.
O'Neil, G.
O'Rourke, M.F.
O'Saughnessy, K.
Ouchi, Y.
Owen, J.S.
Owen, O.E.
Pagani, M.
Palatini, P.
Pannier, B.
Parati, G.
Pare P.
Parfitt, V.
Parker, D.
Parving, H.-H.
Patel, A.
Paterson, C.
Paul, S.
Pavli, P.
Pedersen, O.
Pencharz, P.
Perrelli, M.
Piquette, C.
Pomfrett, C.J.D.
Por, J.N.
Poston, L.
Powell-Tuck, J.
Preedy, V.
Preuss, H.G.
Price, R.G.
Provoost, A.P.
Rabelink, A.
Rampton, D.S.
Reckelhoff, J.F.
Reeds, P.
Reid, J.
Rennie, M.J.
Rerat, A.
Rhodes, J.M.
Rhodes, P.
Rice-Evans, C.
Richard, V.
Ricen, W.F.
Riis Hansen, R.
Rippe, B.
Robbins, R.
Rodger, S.
Romero, J.C.
Ruddy, T.D.
Russell, D.
Russell, F.D.
Rutherford, O.
Ryder, S.
Sagnella, G.A.
Sainsbury, R.
Sands, J.M.
Saruta, T.
Saul, J.P.
Scherrer, U.
Schiffrin, E.L.
Schmieder, R.E.
Schofield, G.G.
Schuppan, D.
Schuyler, M.
Schwarer, A.P.
Selby, W.
Sever, P.
Shenklin, A.
Sheron, N.
Shibayama, Y.
Shioji, M.
Shiota, M.
Shore, A.
Silk, D.B.
Silverman, M.
Simmons, D.
Singer, D.R.J.
Skinner, S.L.
Smit, A.A.J.
Smyth, D.D.
Soutar, A.
Specchia, G.
Spurr, N.
Stalenhoef, A.
Stamp, T.
Starr, J.M.
Stjernstrom, H.
Strauer, B.E.
Strupe, K.O.
Svendsen, O.L.
Sugden, M.
Sundkvist, D.G.
Suzuki, H.
Takeda, K.
Takizawa, H.
Taskinen, M.-R.
Tattersfield, A.
Taylor, K.
Theodore, J.
Thien, Th.
Thompson, A.
Thompson, A.H.
Thorburn, A.
Thuraisingham, R.
Tighe, R.
Tomlinson, D.
Tooke, J.E.
Toska, K.
Tunny, A.N.
Turner, A.N.
Vallance, P.
van de Borne, P.

van Lieshout, J.J.
Van Rij, A.
van Zwieten, P.A.
Vanoli, E.
Vassart, G.
Vassort, G.
Vaz, M.
Verbolis, J.G.
Vetter, H.
Vos, P.
Vyas, H.
Wagenmakers, A.
Wahren, J.
Wallberg- Henrikson, H.
Walker, R.
Ward, S.A.
Wardland, A.J.
Warren, P.M.
Wastell, H.J.
Watson, A.M.
Watt, P.
Weaver, L.
Webb, D.J.
Weinberger, M.
Weise, F.
Wernerman, J.
West, M.
Westerman, R.
White, H.
Whiting, P.
Whyte, M.
Wieling, W.
Wilcox, J.N.
Winocour, P.
Wintour-Coghlan, M.
Winwood, P.J.
Woodsie, B.
Yanagisawa, M.
Yandle, T.
Yeaman, S.J.
Yin, J.A.L.
Young, V.
Zhou, J.
Zidek, W.
Zimmerman, G.
Zinman, B.
<table>
<thead>
<tr>
<th>Author</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdel-Meguid, E.</td>
<td>187–191</td>
</tr>
<tr>
<td>Abdel-Tawab, S.</td>
<td>187–191</td>
</tr>
<tr>
<td>Abu-Amsha, R.</td>
<td>449–458</td>
</tr>
<tr>
<td>Aguiler, M.T.</td>
<td>155–161</td>
</tr>
<tr>
<td>Ainley, C.</td>
<td>219–223</td>
</tr>
<tr>
<td>Albert, J.</td>
<td>225–231</td>
</tr>
<tr>
<td>Allan, P.L.</td>
<td>17–21</td>
</tr>
<tr>
<td>Almada, A.L.</td>
<td>113–118</td>
</tr>
<tr>
<td>Amadi, A.A.</td>
<td>391–398</td>
</tr>
<tr>
<td>Angel, S.E.</td>
<td>99–106</td>
</tr>
<tr>
<td>Armstrong, A.L.</td>
<td>763–769</td>
</tr>
<tr>
<td>Atucha, N.M.</td>
<td>739–743</td>
</tr>
<tr>
<td>Baker, G.</td>
<td>51–58</td>
</tr>
<tr>
<td>Barbara, L.</td>
<td>219–223</td>
</tr>
<tr>
<td>Barden, A.</td>
<td>711–718</td>
</tr>
<tr>
<td>Bassey, E.J.</td>
<td>685–690</td>
</tr>
<tr>
<td>Beilin, L.J.</td>
<td>449–458, 711–718</td>
</tr>
<tr>
<td>Bell, S.C.</td>
<td>169–175</td>
</tr>
<tr>
<td>Benn, J.</td>
<td>575–582</td>
</tr>
<tr>
<td>Bernard, C.</td>
<td>29–33</td>
</tr>
<tr>
<td>Bernardi, L.</td>
<td>35–43</td>
</tr>
<tr>
<td>Bianchetti, M.G.</td>
<td>347–351</td>
</tr>
<tr>
<td>Binah, O.</td>
<td>233–239</td>
</tr>
<tr>
<td>Blakemore, S.J.</td>
<td>591–599</td>
</tr>
<tr>
<td>Bongso, A.</td>
<td>248–249</td>
</tr>
<tr>
<td>Boulton, R.</td>
<td>503–507</td>
</tr>
<tr>
<td>Bourgin, P.</td>
<td>45–50</td>
</tr>
<tr>
<td>Bradford, A.</td>
<td>337–345</td>
</tr>
<tr>
<td>Bragado, M.J.</td>
<td>365–369, 771</td>
</tr>
<tr>
<td>Bragulat, E.</td>
<td>155–161</td>
</tr>
<tr>
<td>Bränström, R.</td>
<td>431–439</td>
</tr>
<tr>
<td>Brögiersen, A.</td>
<td>225–231</td>
</tr>
<tr>
<td>Brown, K.M.</td>
<td>107–111</td>
</tr>
<tr>
<td>Browne, G.</td>
<td>79–86</td>
</tr>
<tr>
<td>Brundin, T.</td>
<td>431–439</td>
</tr>
<tr>
<td>Bund, S.J.</td>
<td>739–743</td>
</tr>
<tr>
<td>Buvry, A.</td>
<td>319–327</td>
</tr>
<tr>
<td>Cacciafest, A.M.</td>
<td>385–389</td>
</tr>
<tr>
<td>Cailmail, S.</td>
<td>29–33</td>
</tr>
<tr>
<td>Calverley, P.M.A.</td>
<td>513–518</td>
</tr>
<tr>
<td>Calvo, J.J.</td>
<td>365–369, 771</td>
</tr>
<tr>
<td>Campbell, B.J.</td>
<td>359–364</td>
</tr>
<tr>
<td>Canali, C.</td>
<td>275–281</td>
</tr>
<tr>
<td>Carter, J.</td>
<td>513–518</td>
</tr>
<tr>
<td>Cartouzou, G.</td>
<td>209–212</td>
</tr>
<tr>
<td>Carver, J.G.</td>
<td>725–731</td>
</tr>
<tr>
<td>Caso, G.</td>
<td>99–106</td>
</tr>
<tr>
<td>Cassell, T.B.</td>
<td>509–512</td>
</tr>
<tr>
<td>Castleden, C.M.</td>
<td>467–474</td>
</tr>
<tr>
<td>Cattell, V.</td>
<td>375–384</td>
</tr>
<tr>
<td>Celli, V.</td>
<td>385–389</td>
</tr>
<tr>
<td>Cester, N.</td>
<td>719–723</td>
</tr>
<tr>
<td>Chadwick, I.G.</td>
<td>617–620</td>
</tr>
<tr>
<td>Chan, S.H.</td>
<td>256–258</td>
</tr>
<tr>
<td>Chan, S.Y.</td>
<td>250–252</td>
</tr>
<tr>
<td>Charles, C.J.</td>
<td>283–291</td>
</tr>
<tr>
<td>Chin-Dusting, J.</td>
<td>23–28</td>
</tr>
<tr>
<td>Christensen, N.J.</td>
<td>621–626</td>
</tr>
<tr>
<td>Chua, T.P.</td>
<td>391–398</td>
</tr>
<tr>
<td>Cipollina, M.R.</td>
<td>703–710</td>
</tr>
<tr>
<td>Claassen, J.A.H.R.</td>
<td>483–488</td>
</tr>
<tr>
<td>Claude, J.E.</td>
<td>513–518</td>
</tr>
<tr>
<td>Clark, M.L.</td>
<td>425–430</td>
</tr>
<tr>
<td>Coats, A.J.S.</td>
<td>391–398</td>
</tr>
<tr>
<td>Coca, A.</td>
<td>155–161</td>
</tr>
<tr>
<td>Colombani, V.</td>
<td>209–212</td>
</tr>
<tr>
<td>Colombo, R.</td>
<td>391–398</td>
</tr>
<tr>
<td>Compston, J.E.</td>
<td>307–312</td>
</tr>
<tr>
<td>Connell, J.M.C.</td>
<td>65–71</td>
</tr>
<tr>
<td>Cook, H.T.</td>
<td>375–384</td>
</tr>
<tr>
<td>Coupland, C.A.C.</td>
<td>685–690</td>
</tr>
<tr>
<td>Cowley, A.J.</td>
<td>415–423</td>
</tr>
<tr>
<td>Crawley, J.</td>
<td>51–58</td>
</tr>
<tr>
<td>Crijs, F.R.L.</td>
<td>131–139</td>
</tr>
<tr>
<td>Critchley, J.A.J.H.</td>
<td>35–43</td>
</tr>
<tr>
<td>Croft, K.D.</td>
<td>449–458, 711–718</td>
</tr>
<tr>
<td>Curran, A.K.</td>
<td>337–345</td>
</tr>
<tr>
<td>D'Almeida, M.</td>
<td>29–33</td>
</tr>
<tr>
<td>Davies, P.S.W.</td>
<td>763–769</td>
</tr>
<tr>
<td>Day, J.M.E.</td>
<td>763–769</td>
</tr>
<tr>
<td>de Silva, H.A.</td>
<td>725–731</td>
</tr>
<tr>
<td>De Chazal, R.</td>
<td>169–175</td>
</tr>
<tr>
<td>De La Sierra, A.</td>
<td>155–161</td>
</tr>
<tr>
<td>De Leeuw, P.W.</td>
<td>163–168</td>
</tr>
<tr>
<td>De Propis, A.M.</td>
<td>385–389</td>
</tr>
<tr>
<td>De Rooij, M.J.M.</td>
<td>483–488</td>
</tr>
<tr>
<td>Del Mar Lluch, M.</td>
<td>155–161</td>
</tr>
<tr>
<td>Dessauer, C.W.</td>
<td>527–537</td>
</tr>
<tr>
<td>Di Bernardo, M.G.</td>
<td>385–389</td>
</tr>
<tr>
<td>Di Virgilio, F.</td>
<td>703–710</td>
</tr>
<tr>
<td>Dickinson, C.J.</td>
<td>539–550</td>
</tr>
<tr>
<td>Dimitriadou, V.</td>
<td>319–327</td>
</tr>
<tr>
<td>Ding, X.-J.</td>
<td>93–98</td>
</tr>
<tr>
<td>Dowling, R.H.</td>
<td>509–512</td>
</tr>
<tr>
<td>Drummond, P.D.</td>
<td>73–77</td>
</tr>
<tr>
<td>Dudley, F.</td>
<td>23–28</td>
</tr>
<tr>
<td>Duner, E.</td>
<td>703–710</td>
</tr>
<tr>
<td>Duthie, G.G.</td>
<td>107–111</td>
</tr>
<tr>
<td>Dutto, F.</td>
<td>313–318</td>
</tr>
<tr>
<td>Earnest, C.P.</td>
<td>113–118</td>
</tr>
<tr>
<td>El-Gamal, N.</td>
<td>627–631</td>
</tr>
<tr>
<td>Elliott, H.L.</td>
<td>65–71</td>
</tr>
<tr>
<td>Elliott, R.A.</td>
<td>467–474</td>
</tr>
<tr>
<td>Ellory, J.C.</td>
<td>353–358</td>
</tr>
<tr>
<td>Engelman, J.L.</td>
<td>500–512</td>
</tr>
<tr>
<td>Escourrou, P.</td>
<td>45–50</td>
</tr>
<tr>
<td>Espiner, E.A.</td>
<td>283–291</td>
</tr>
<tr>
<td>Essén, P.</td>
<td>99–106</td>
</tr>
<tr>
<td>Eto, T.</td>
<td>293–298</td>
</tr>
<tr>
<td>Fagbemi, O.S.</td>
<td>745–754</td>
</tr>
<tr>
<td>Farag, M.M.</td>
<td>187–191</td>
</tr>
<tr>
<td>Farmer, R.D.T.</td>
<td>87–92</td>
</tr>
<tr>
<td>Farzaneh, F.</td>
<td>213–218</td>
</tr>
<tr>
<td>Feigel, P.</td>
<td>45–50</td>
</tr>
<tr>
<td>Felzen, B.</td>
<td>233–239</td>
</tr>
<tr>
<td>Feng, Y.-H.</td>
<td>459–466</td>
</tr>
<tr>
<td>Finch, P.M.</td>
<td>73–77</td>
</tr>
<tr>
<td>Finnie, I.A.</td>
<td>359–364</td>
</tr>
<tr>
<td>Flanagan, G.J.</td>
<td>353–358</td>
</tr>
<tr>
<td>Forster, C.D.</td>
<td>425–430</td>
</tr>
<tr>
<td>Fortepiani, L.A.</td>
<td>733–738</td>
</tr>
<tr>
<td>Fowler, B.</td>
<td>79–86</td>
</tr>
<tr>
<td>Frank, S.M.</td>
<td>627–631</td>
</tr>
<tr>
<td>Frayn, K.N.</td>
<td>425–430, 679–683</td>
</tr>
<tr>
<td>Freestone, S.</td>
<td>177–185</td>
</tr>
<tr>
<td>Frick, G.</td>
<td>79–86</td>
</tr>
<tr>
<td>Frossard, N.</td>
<td>319–327</td>
</tr>
<tr>
<td>Frostell, C.</td>
<td>225–231</td>
</tr>
<tr>
<td>Gafter, U.</td>
<td>519–523</td>
</tr>
<tr>
<td>Garbarg, M.</td>
<td>319–327</td>
</tr>
<tr>
<td>Garcia, L.J.</td>
<td>365–369, 771</td>
</tr>
<tr>
<td>Garcia-Esthañ, J.</td>
<td>733–738</td>
</tr>
<tr>
<td>Garlick, P.J.</td>
<td>99–106</td>
</tr>
<tr>
<td>Gaskin, G.</td>
<td>329–335</td>
</tr>
<tr>
<td>Gerolami, A.</td>
<td>209–212</td>
</tr>
<tr>
<td>Ghosh, S.</td>
<td>213–218</td>
</tr>
<tr>
<td>Gibson, A.</td>
<td>633–638</td>
</tr>
<tr>
<td>Gilman, A.G.</td>
<td>527–537</td>
</tr>
<tr>
<td>Giner, V.</td>
<td>155–161</td>
</tr>
<tr>
<td>Giordano, A.</td>
<td>391–398</td>
</tr>
<tr>
<td>Glenville, B.</td>
<td>51–58</td>
</tr>
<tr>
<td>Goldman, J.M.</td>
<td>329–335</td>
</tr>
</tbody>
</table>
## Subject Index

First and last page numbers of papers to which entries refer are given. Page numbers marked with an asterisk refer to Reviews.

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accidental falls oestrogen replacement therapy</td>
<td>685–690</td>
</tr>
<tr>
<td>Acetylcholine endothelium, Syndrome X</td>
<td>739–743</td>
</tr>
<tr>
<td>nitric oxide, liver cirrhosis</td>
<td>733–738</td>
</tr>
<tr>
<td>Action potential cardiac muscle, nutritional iron deficiency</td>
<td>233–239</td>
</tr>
<tr>
<td>Activation energy Na⁺, K⁺-ATPase, gestational hypertension</td>
<td>719–723</td>
</tr>
<tr>
<td>S-Adenosylhomocysteine metabolism</td>
<td>79–86</td>
</tr>
<tr>
<td>S-Adenosylmethionine metabolism</td>
<td>79–86</td>
</tr>
<tr>
<td>Adenylate cyclase G-proteins, signal transduction</td>
<td>527–537*</td>
</tr>
<tr>
<td>Adipose tissue microdialysis catecholamines</td>
<td>425–430</td>
</tr>
<tr>
<td>Adipose tissue blood flow body mass index</td>
<td>679–683</td>
</tr>
<tr>
<td>Adrenaline lymphocytes, cyclic AMP</td>
<td>612–626</td>
</tr>
<tr>
<td>α-Adrenergic receptors skin, reflex sympathetic dystrophy</td>
<td>73–77</td>
</tr>
<tr>
<td>Adrenergic β₂-receptors lymphocytes, noradrenaline</td>
<td>621–626</td>
</tr>
<tr>
<td>α-Adrenoceptor antagonist thermoregulation</td>
<td>627–631</td>
</tr>
<tr>
<td>Adrenomedullin G-protein-linked receptors, cyclic AMP</td>
<td>3–16*, 525</td>
</tr>
<tr>
<td>salt, essential hypertension</td>
<td>293–298</td>
</tr>
<tr>
<td>Ageing lymphocytes, cyclic AMP</td>
<td>621–626</td>
</tr>
<tr>
<td>Alcohol pancreatitis-associated protein messenger RNA</td>
<td>213–218</td>
</tr>
<tr>
<td>Alcoholic cirrhosis nitric oxide</td>
<td>23–28</td>
</tr>
<tr>
<td>Aliphatic amines renal failure, choline transport</td>
<td>353–358</td>
</tr>
<tr>
<td>Alkalosis hyperventilation, magnesium</td>
<td>347–351</td>
</tr>
<tr>
<td>Almitrine ventilation, muscle activity</td>
<td>337–345</td>
</tr>
<tr>
<td>Ambulatory blood pressure left ventricular function, hypertension</td>
<td>275–281</td>
</tr>
<tr>
<td>Ambulatory monitoring blood pressure, sleep</td>
<td>45–50</td>
</tr>
<tr>
<td>Amino acids inflammation, cytokines</td>
<td>121–130*</td>
</tr>
<tr>
<td>metabolism, vascular disease</td>
<td>79–86</td>
</tr>
<tr>
<td>renal transplant recipients, cyclosporin A</td>
<td>489–496</td>
</tr>
<tr>
<td>thermogenesis, anaesthesia</td>
<td>431–439</td>
</tr>
<tr>
<td>Aminoglycosides nephrotoxicity, non-steroidal anti-inflammatory drugs</td>
<td>187–191</td>
</tr>
<tr>
<td>Amylase release pancreatitis</td>
<td>365–369, 771</td>
</tr>
<tr>
<td>Anaesthesia amino acids, thermogenesis</td>
<td>431–439</td>
</tr>
<tr>
<td>Angina cholesterol, lipids</td>
<td>399–413, 773–774</td>
</tr>
<tr>
<td>Angiotensin II microalbuminuria, non-insulin-dependent diabetes</td>
<td>703–710</td>
</tr>
<tr>
<td>Angiotensin type 1 receptor antagonists renal vasodilatation, spontaneously hypertensive rats</td>
<td>147–154</td>
</tr>
<tr>
<td>Angiotensin-converting enzyme genetic polymorphism, bradykinin</td>
<td>617–620</td>
</tr>
<tr>
<td>Antioxidant enzyme vitamin E, smoking</td>
<td>107–111</td>
</tr>
<tr>
<td>Antioxidants inflammation, cytokines</td>
<td>121–130*</td>
</tr>
<tr>
<td>Antisense oligodeoxynucleotides multidrug resistance</td>
<td>93–98</td>
</tr>
<tr>
<td>Aorta nitric oxide, liver cirrhosis</td>
<td>733–738</td>
</tr>
<tr>
<td>Arachidonic acid phospholipids, Crohn’s disease</td>
<td>509–512</td>
</tr>
<tr>
<td>Arterialization insulin sensitivity, forearm blood flow</td>
<td>65–71</td>
</tr>
<tr>
<td>Artery morphology, syndrome X</td>
<td>739–743</td>
</tr>
<tr>
<td>ATP synthesis</td>
<td></td>
</tr>
</tbody>
</table>
Subject Index

exercise, obesity 691–702
ATP-sensitive potassium channels 651–663*
potassium channel openers 651–663*
Atrial natriuretic peptide
neutral endopeptidase, ventricular pacing 283–291
salt, essential hypertension 293–298
potassium channel openers 651–663*
Autoantigen
T-lymphocytes, biliary cirrhosis 551–558
Autoimmunity
T-lymphocytes, biliary cirrhosis 551–558
Autonomic function
baroreflex sensitivity, insulin-dependent diabetes mellitus 59–64
Autonomic nervous system
heart failure, heart rate variability 391–398
heart failure, spectral power 35–43
Poincaré plot, heart rate variability 201–208
Autoregulation
Na+, K+-ATPase, ouabain 497–502
Balance
oestrogen replacement therapy 685–690
Baroreflex sensitivity
autonomic function, insulin-dependent diabetes mellitus 59–64
Bicarbonate-urea method
energy expenditure, human immunodeficiency virus infection 241–245
Biliary cirrhosis
autoimmunity, T-lymphocytes 551–558
Blastocyst transfer
human embryos 248–249
Bleeding time
inhaled nitric oxide 225–231
Blood flow
vascular disease, ultrasound 17–21
Blood pressure
ambulatory monitoring, sleep 45–50
stroke volume, syncope 193–200
Blood temperature
amino acids, anaesthesia 431–439
Blood transfusion
T-helper 2 cytokines, transforming growth factor 519–523
Body composition
chronic kidney failure 763–769
Body mass index
adipose tissue blood flow 679–683
Bone mineral density
postmenopausal women 307–312
Bone resorption
calcium nephrolithiasis, mineral water 313–318
Bradykinin
angiotensin-converting enzyme, genetic polymorphism 617–620
endothelium, Syndrome X 739–743
Brain
oxidative metabolism, hypertension 539–550
Brain natriuretic peptide
neutral endopeptidase, ventricular pacing 283–291
Breath-holding time
control of breathing, dyspnoea 755–761
Bronchial hyper-responsiveness
lung transplantation, mast cells 319–327
Bumetanide
Na⁺/K⁺/2Cl⁻ co-transport 725–731
Caerulein
pancreatitis, intracellular calcium 365–369, 771
Caffeic acid
lipoprotein oxidation, wine 449–458
Calcium
alkalosis, hyperventilation 347–351
Calcium antagonist
oxidants 459–466
urinary bladder 467–474
Calcium nephrolithiasis
mineral water 313–318
Calcium oxalate
urine state of saturation, calcium nephrolithiasis 313–318
Calcium phosphate
urine state of saturation, calcium nephrolithiasis 313–318
Calf muscle pump function
validation, chronic venous insufficiency 483–488
Cancer
eicosanoid production 264–266
Helicobacter pylori, serology 219–223
Capillaroscopy
microcirculation 131–139*
Capsaicin
chilli, stomach 252–254
Carbon dioxide
inspiratory effort sensation, sustained loading 513–518
recovery 665–677
Cardiac muscle
nutritional iron deficiency 233–239
Cardiac oxygenation
ischaemia, spectrophotometry 51–58
Catalase
diabetes 441–448
Catecholamines
adipose tissue, microdialysis 425–430
Cell adhesion
epidermal stem cells, integrins 141–146*
Cell adhesion molecules  
  integrins 639–650
Cell differentiation  
  epidermal stem cells 141–146
Cell division  
  epidermal stem cells 141–146
Cell proliferation  
  epidermal growth factor, gastrointestinal tract 503–507
Cerebral blood supply  
  hypertension 539–550
Cerebrovascular disease  
  hypertension 539–550
Cervical carcinoma  
  DNA testing, papillomavirus 250–252
Chemiluminescence  
  oxidants, calcium antagonist 459–466
Chemoreceptors  
  heart failure, heart rate variability 391–398
Chilli  
  capsaicin, stomach 252–254
Cholecystokinin 8  
  intracellular calcium, pancreatitis 365–369, 771
Cholesterol  
  coronary heart disease, lipids 399–413, 773–774
Cholesterol metabolism  
  creatine supplementation 113–118
Choline transport  
  renal failure, haemodialysis 353–358
Chronic kidney failure  
  body composition 763–769
Chronic venous insufficiency  
  calf muscle pump function, validation 483–488
Cirrhosis  
  tumour necrosis factor-α, pentoxifylline 29–33
Clinical research  
  progress in Singapore 247–266
Colonic mucin  
  corticosteroids, nicotine 359–364
Contractile response  
  portal hypertension, octreotide 601–606
Contractility  
  cardiac muscle, nutritional iron deficiency 233–239
Control of breathing  
  breath-holding time, dyspnoea 755–761
Coronary heart disease  
  cholesterol, lipids 399–413, 773–774
Coronary risk  
  lipids 399–413, 773–774
Corticosteroids  
  mucin, colon 359–364
Creatine supplementation  
  lipid metabolism 113–118
Crohn’s disease  
  fatty acids, phospholipids 509–512
Cromakalim  
  therapeutic targets 651–663
CV-11974  
  renal vasodilatation, spontaneously hypertensive rats 147–154
Cyclic AMP  
  G-protein-linked receptors, adrenomedullin 3–16*, 525
  G-proteins, signal transduction 527–537
  lymphocytes, noradrenaline 621–626
Cyclic GMP  
  inhaled nitric oxide 225–231
  neutral endopeptidase, ventricular pacing 283–291
Cyclosporin A  
  renal transplant recipients 489–496
Cytochrome aa₃  
  ischaemia, spectrophotometry 51–58
Cytochrome c oxidase  
  muscle wasting, zymosan 475–481
Cytokine  
  pentoxifylline, cirrhosis 29–33
Cytokines  
  nutrients, inflammation 121–130
Densitometry  
  chronic kidney failure 763–769
Dermis  
  α-adrenergic receptors, reflex sympathetic dystrophy 73–77
Diabetes  
  endothelium, dyslipidaemia 567–573
  microcirculation 131–139
  oxidative stress 441–448
  oxidative stress, glyoxylase 575–582
Diabetes mellitus  
  baroreflex sensitivity, autonomic function 59–64
Diabetic foot  
  skin microcirculation, neuropathy 559–565
Diaphragm  
  almitrine, electromyography 337–345
Diclofenac sodium  
  nephrotoxicity, gentamicin 187–191
DNA testing  
  papillomavirus, cervical carcinoma 250–252
Dopamine  
  5-hydroxytryptamine, renal sodium excretion 177–185
  renal transplant recipients, cyclosporin A 489–496
Dyslipidaemia  
  diabetes, endothelium 567–573
Dyspnoea
control of breathing, breath-holding time 755–761
Echocardiography
  left ventricular function, hypertension 275–281
EEG arousal
  blood pressure, sleep 45–50
Eicosanoid production
  hypertension, cancer 264–266
Electromyography
  muscle activity, almitrine 337–345
Embryos
  blastocyst transfer, stem cell production 248–249
Endothelin
  salt, essential hypertension 293–298
Endothelin peptides
  human kidney 267–273*
Endothelin receptors
  human kidney 267–273*
Endothelium
  diabetes, dyslipidaemia 567–573
  phenylephrine, liver cirrhosis 733–738
  Syndrome X 739–743
Energy expenditure
  bicarbonate-urea method, human immunodeficiency virus infection 241–245
Epidermal growth factor
  cell proliferation, gastrointestinal tract 503–507
Epidermal stem cells
  cell adhesion, integrins 141–146*
Epidermis
  \( \alpha \)-adrenergic receptors, reflex sympathetic dystrophy 73–77
Epilepsy
  genetic analysis 264–266
Erythropoietin dysregulation
  renal failure 258–260
Essential hypertension
  salt, adrenomedullin 293–298
Exercise
  ATP synthesis, obesity 691–702
EXP 3174
  renal vasodilatation, spontaneously hypertensive rats 147–154
Familial hypokalaemic periodic paralysis
  sodium pump 261–264
Fatiguability
  cytochrome \( c \) oxidase, zymosan 475–481
Fatigue
  inspiratory effort sensation, \( \text{CO}_2 \) responsiveness 513–518
Fats
  inflammation, cytokines 121–130*
Fatty acids
  phospholipids, Crohn's disease 509–512
Fetal programming
  maternal nutrition, hypertension 607–615
Fetuses
  gestational age, kidney 169–175
Fibroblasts
  intracellular pH, free cytosolic calcium 703–710
Flooding dose
  muscle wasting, zymosan 475–481
Fluidity
  \( \text{Na}^+, \text{K}^+-\text{ATPase} \), gestational hypertension 719–723
Fluoxetine
  5-hydroxytryptamine, platelet aggregation 87–92
Forearm blood flow
  arterialization 65–71
  menstrual cycle 163–168
Free cytosolic calcium
  microalbuminuria, non-insulin-dependent diabetes 703–710
Fruconide
  sodium depletion 299–305
Gallbladder
  sodium/hydrogen exchanger, sodium absorption 209–212
Gastrointestinal tract
  cell proliferation, epidermal growth factor 503–507
Gene expression
  pancreatitis-associated protein, mouse intestine 213–218
Genetic analysis
  research in Singapore 264–266
Genetic polymorphism
  angiotensin-converting enzyme, bradykinin 617–620
Geniohyoid
  almitrine, electromyography 337–345
Gentamicin
  nephrotoxicity, non-steroidal anti-inflammatory drugs 187–191
Gestational age
  renin, kidney 169–175
Gestational hypertension
  \( \text{Na}^+, \text{K}^+-\text{ATPase} \) 719–723
Glomerular filtration rate
  renal transplant recipients, cyclosporin A 489–496
Glomerulonephritis
  IgA nephropathy 258–260
Glucocorticoids
  fetal programming, hypertension 607–615
Glucose transport
  sarcolemma, insulin 591–599
Gludopa
renal metabolism 177–185
γ-L-Glutamyl-5-hydroxy-L-tryptophan
renal metabolism 177–185
Glutathione
antioxidants, cytokines 121–130*
Glutathione peroxidase
diabetes 441–448
Glycogenolysis
exercise, obesity 691–702
Glyoxal
diabetes, oxidative stress 575–582
Glyoxylase
diabetes, oxidative stress 575–582
G-protein-linked receptors
adrenomedullin, cyclic AMP 3–16*, 525
G-proteins
signal transduction, adenylate cyclase 527–537*
Granulocyte activation
inflammatory disease 329–335
Granulocyte pool
111In-99mTc-labelled granulocytes, inflammatory
disease 329–335
Grape juice
phenolic compounds, lipoprotein oxidation 449–458
Growth hormone
male infertility 254–256
Haemodialysis
blood transfusion 519–523
renal failure, choline transport 353–358
Haemodynamics
ischaemia, spectrophotometry 51–58
meal ingestion, insulin 415–423
neutral endopeptidase, ventricular pacing 283–291
pentoxifylline, cirrhosis 29–33
Heart failure
adrenomedullin 3–16*, 525
autonomic nervous system, spectral power 35–43
heart rate variability, autonomic nervous system 391–398
Heart rate
blood pressure, sleep 45–50
Heart rate variability
autonomic nervous system, spectral power 35–43
heart failure, autonomic nervous system 391–398
Poincaré plot, parasympathetic nervous system 201–208
Helicobacter pylori
serology, cancer 219–223
High-performance liquid chromatography
non-transferrin-bound iron, preterm babies 633–638
Hip
bone-mineral density, postmenopausal women 307–312
Homocysteine
metabolism 79–86
Hormone replacement therapy
bone mineral density, postmenopausal women 307–312
Human immunodeficiency virus infection
energy expenditure, bicarbonate-urea method 241–245
Human leucocyte antigens
nasopharyngeal carcinoma 256–258
5-Hydroxytryptamine
dopamine, renal sodium excretion 177–185
platelet aggregation, fluoxetine 87–92
Hyperglycaemia
insulin release, muscle strength 583–589
Hyperinsulinaemic euglycaemic clamp
insulin sensitivity, arterialization 65–71
Hypertension
adrenomedullin 3–16*, 525
contractile response, octreotide 601–606
eicosanoid production 264–266
fetal programming, maternal nutrition 607–615
left ventricular function,
echocardiography 275–281
microcirculation 131–139*
Na⁺, K⁺-ATPase, ouabain 497–502
oxidative metabolism, brain 539–550
renin, gestational age 169–175
salt, adrenomedullin 293–298
salt sensitivity 155–161
Hyperventilation
alkalosis, magnesium 347–351
Hypokalaemic periodic paralysis
insulin release 583–589
sodium pump 261–264
Hypometabolism
amino acids, anaesthesia 431–439
Hypotension
stroke volume, syncope 193–200
Hypothermia
α-adrenoceptor antagonist 627–631
amino acids, anaesthesia 431–439
Hypothermic preservation
rat heart, protein kinase C inhibitors 745–754
Hypoxia
pancreatitis-associated protein messenger RNA 213–218
Ibuprofen
nephrotoxicity, gentamicin 187–191
IgA nephropathy
primary glomerulonephritis 258–260
Immune complex disease
  inflammation mediators, nitric oxide 375–384*
Immunity
  nitric oxide 375–384*
Immunostaining
  mast cells, lung transplantation 319–327
  $^{111}$In-99mTc-labelled granulocytes
  lung granulocyte pool, inflammatory
disease 329–335
Infertility
  growth hormone 254–256
Inflammation
  nutrients, cytokines 121–130*
Inflammation mediators
  nitric oxide, immune complex disease 375–384*
Inflammatory disease
  granulocyte activation, lung granulocyte
  pool 329–335
Inhaled nitric oxide
  platelet function 225–231
Innervation
  lung transplantation 319–327
Inspiratory effort sensation
  $\text{CO}_2$ responsiveness, sustained loading 513–518
Insulin
  adipose tissue blood flow 679–683
  glucose transport, sarcolemma 591–599
  microalbuminuria, non-insulin-dependent
diabetes 703–710
  regional haemodynamics, meal
  ingestion 415–423
Insulin release
  hypokalaemic periodic paralysis 583–589
Insulin sensitivity
  arterialization 65–71
Insulin-dependent diabetes mellitus
  baroreflex sensitivity, autonomic function 59–64
Integrins
  cell adhesion, epidermal stem cells 141–146*
  cell adhesion molecules 639–650*
Interleukin
  blood transfusion 519–523
  nutrients, inflammation 121–130*
Intracellular calcium
  pancreatitis 365–369, 771
Intracellular pH
  microalbuminuria, non-insulin-dependent
diabetes 703–710
Intravenous nutrition
  epidermal growth factor 503–507
Intravital microscopy
  microcirculation 131–139*
Inulin clearance
  menstrual cycle 163–168
Iron deficiency
  pancreatitis-associated protein
  messenger RNA 213–218
Iron overload
  pancreatitis-associated protein
  messenger RNA 213–218
Ischaemia
  cardiac oxygenation, spectrophotometry 51–58
  oxidants, calcium antagonist 459–466
Iso-electric focusing
  serology, cancer 219–223
Iso-prostane
  lipid peroxidation, pregnancy 711–718
Keratinocytes
  epidermal stem cells 141–146*
Kidney
  endothelins 267–273*
  fetal programming, hypertension 607–615
  renin, gestational age 169–175
Labelled carbon dioxide
  recovery 665–77
Left ventricular function
  echocardiography, hypertension 275–281
Lipid
  neutrophils, sepsis 371–374
Lipid metabolism
  creatinine supplementation 113–118
Lipid peroxidation
  diabetes 441–448
  pre-eclampsia, pregnancy 711–718
  vitamin E, smoking 107–111
Lipids
  coronary heart disease, cholesterol 399–413,
  773–774
Lipoprotein oxidation
  phenolic compounds, wine 449–458
Lithium clearance
  renal transplant recipients, cy closporin A 489–496
Liver
  autoimmunity, T-lymphocytes 551–558
Liver cirrhosis
  phenylephrine, nitric oxide 733–738
Loop of Henle
  sodium depletion, frusemide 299–305
Loss of label
  carbon dioxide 665–677
Lung granulocyte pool
  $^{111}$In-99mTc-labelled granulocytes, inflammatory
disease 329–335
Lung transplantation
  mast cells, bronchial
  hyper-responsiveness 319–327
Lymphocytes
  cyclic AMP, noradrenaline 621–626
  protein synthesis, stable isotope 99–106
Magnesium
  alkalosis, hyperventilation 347–351
Magnetic resonance spectroscopy
  ATP synthesis 691–702
Male infertility
  growth hormone 254–256
Mast cells
  lung transplantation, bronchial
    hyper-responsiveness 319–327
Maternal nutrition
  fetal programming, hypertension 607–615
Meal ingestion
  regional haemodynamics, insulin 415–423
Mean arterial pressure
  metabolic risk factors, sex 385–389
Membrane
  sarcolemma, glucose transport 591–599
  cardiac muscle, nutritional iron
deficiency 233–239
Menstrual cycle
  sex hormones, vascular relaxation 163–168
Mesenteric artery
  contractile response, octreotide 601–606
Messenger RNA
  pancreatitis-associated protein, mouse
    intestine 213–218
  metabolic risk factors, blood pressure, sex 385–389
Metabolism
  amino acids, vascular disease 79–86
    thermoregulation, α-adrenoceptor antagonist 627–631
Methodology
  labelled carbon dioxide, recovery 665–677
Methylglyoxal
  diabetes, oxidative stress 575–582
5-Methyltetrahydrofolate
  metabolism 79–86
Microalbuminuria
  intracellular pH, free cytosolic calcium 703–710
Microcirculation
  cardiovascular disease 131–139*
    diabetic foot, neuropathy 559–565
Microdialysis
  adipose tissue, catecholamines 425–430
Microperfusion
  loop of Henle, frusemide 299–305
Micropuncture
  sodium depletion, frusemide 299–305
Mineral water
  calcium nephrolithiasis 313–318
Mitochondria
  ischaemia, spectrophotometry 51–58
Morphology
  artery, Syndrome X 739–743
Mouse intestine
  pancreatitis-associated protein, messenger RNA 213–218
Mucin
corticosteroids, nicotine 359–364
Multidrug resistance
  antisense oligodeoxynucleotides 93–98
Muscle
  oestrogen replacement therapy 685–690
  exercise, obesity 691–702
Muscle strength
  hypokalaemic periodic paralysis 583–589
  wasting 475–481
Myocardial infarction
  cholesterol, lipids 399–413, 773–774
Na+/K+/2Cl– co-transport
  platelets 725–731
Na+, K+-ATPase
  gestational hypertension 719–723
    ouabain, hypertension 497–502
Nasopharyngeal carcinoma
  human leucocyte antigens 256–258
Natriuresis
  adrenomedullin 3–16*, 525
    neutral endopeptidase, ventricular pacing 283–291
Natriuretic peptides
  neutral endopeptidase, ventricular pacing 283–291
Natural killer cells
  cyclic AMP, noradrenaline 621–626
Nephrotoxicity
  gentamicin, non-steroidal anti-inflammatory drugs 187–191
Neuropathy
  diabetic foot, skin microcirculation 559–565
  neutral endopeptidase, ventricular pacing 283–291
Neutrophils
  total parenteral nutrition, sepsis 371–374
Nicotine
  mucin, colon 359–364
Nitric oxide
  alcoholic cirrhosis 23–28
    diabetes, dyslipidaemia 567–573
    immunity 375–384*
    phenylephrine, liver cirrhosis 733–738
    platelet function 225–231
Nitric oxide synthase
  immunity 375–384*
Non-insulin-dependent diabetes
  intracellular pH, free cytosolic calcium 703–710
Non-steroidal anti-inflammatory drugs
  nephrotoxicity, gentamicin 187–191
Non-transferrin-bound iron
  high-performance liquid chromatography, preterm babies 633–638
Noradrenaline
  lymphocytes, cyclic AMP 621–626
Subject Index

salt sensitivity, hypertension 155–161
Nutrients
  inflammation, cytokines 121–130 *
Nutritional iron deficiency
  cardiac muscle 233–239
Obesity
  adipose tissue blood flow 679–683
  ATP synthesis, exercise 691–702
Octrétide
  contractile response, portal hypertension 601–606
Oestrogen replacement therapy
  muscle, balance 685–690
Ouabain
  Na+, K+-ATPase, hypertension 497–502
Oxidants
  calcium antagonist 459–466
Oxidation
  exercise, obesity 691–702
Oxidative metabolism
  brain, hypertension 539–550
Oxidative stress
  diabetes 441–448
  diabetes, glyoxylase 575–582
Oxygen consumption
  oxidants, calcium antagonist 459–466
Pancreatic acinar cells
  intracellular calcium, pancreatitis 365–369, 771
Pancreatitis
  intracellular calcium 365–369, 771
  pancreatitis-associated protein messenger RNA, mouse intestine 213–218
Papillomavirus
  DNA testing, cervical carcinoma 250–252
Para-aminohippurate clearance
  menstrual cycle 163–168
Parasympathetic nervous system
  Poincaré plot, heart rate variability 201–208
Parenteral nutrition
  epidermal growth factor 503–507
Pentoxifylline
  tumour necrosis factor-α, cirrhosis 29–33
Phagocytosis
  oxidants, calcium antagonist 459–466
Phenolic compounds
  lipoprotein oxidation, wine 449–458
Phentolamine
  thermoregulation 627–631
Phenylephrine
  contractile response, octreotide 601–606
  nitric oxide, liver cirrhosis 733–738
Phosphocreatine breakdown
  exercise, obesity 691–702
Phospholipids
  fatty acids, Crohn’s disease 509–512
Physical activity
  bicarbonate-urea method, human immunodeficiency virus infection 241–245
  Physical fitness
    lymphocytes, cyclic AMP 621–626
Phenacidiol
  insulin release, muscle strength 583–589
Placenta
  Na+, K+-ATPase, gestational hypertension 719–723
Platelet aggregation
  5-hydroxytryptamine, fluoxetine 87–92
  inhaled nitric oxide 225–231
Platelets
  Na+/K+/2Cl– co-transport 725–731
Plethysmography
  calf muscle pump function 483–488
  forearm blood flow, arterialization 65–71
Poincaré plot
  parasympathetic nervous system, heart rate variability 201–208
Polymerase chain reaction
  renal endotheilins 267–273 *
Portal hypertension
  contractile response, octreotide 601–606
  pentoxifylline, cirrhosis 29–33
Post-menopause
  oestrogen replacement therapy 685–690
Post-thrombotic syndrome
  calf muscle pump function, validation 483–488
Postmenopausal women
  bone mineral density 307–312
Posture
  spectral power 35–43
Potassium
  alkalosis, hyperventilation 347–351
Potassium channel openers
  therapeutic targets 651–663 *
Pre-eclampsia
  lipid peroxidation 711–718
Pregnancy
  lipid peroxidation 711–718
Pressure natriuresis
  Na+, K+-ATPase, ouabain 497–502
Preterm babies
  non-transferrin-bound iron, high-performance liquid chromatography 633–638
Primary prevention
  coronary heart disease 399–413, 773–774
Protease
  mast cells, lung transplantation 319–327
Protein kinase C inhibitors
  rat heart, hypothermic preservation 745–754
Protein synthesis
  lymphocytes, stable isotope 99–106
Pulse pressure
  metabolic risk factors, sex 385–389
Rat heart
  hypothermic preservation, protein kinase C inhibitors 745–754
Recovery
labelled carbon dioxide 665–677
Reflex sympathetic dystrophy 
\(\alpha\)-adrenergic receptors, skin 73–77
Renal endothelins 
quantitative polymerase chain reaction analysis 267–273*
Renal failure 
choline transport, haemodialysis 353–358 
erythropoietin dysregulation 258–260
Renal plasma flow 
renal transplant recipients, cyclosporin A 489–496
Renal sodium excretion 
dopamine, 5-hydroxytryptamine 177–185
Renal transplant recipients 
amino acids, dopamine 489–496 
Renal tubule 
sodium depletion, frusemide 299–305
Renal vasodilatation 
angiotensin type 1 receptor antagonists, spontaneously hypertensive rats 147–154
Renin 
gestational age, kidney 169–175
Renin–aldosterone axis 
salt sensitivity, hypertension 155–161
Resistance arteries 
nitric oxide, alcoholic cirrhosis 23–28
Respiratory frequency 
spectral power 35–43
Salt 
adrenomedullin, essential hypertension 293–298
Salt sensitivity 
hypertension 155–161
Sarcolemma 
glucose transport, insulin 591–599
Schizophrenia 
genetic analysis 264–266
Secondary prevention 
coronary heart disease 399–413, 773–774
Sepsis 
neutrophils, total parenteral nutrition 371–374
Serology 
*Helicobacter pylori*, cancer 219–223
Sex 
metabolic risk factors, blood pressure 385–389
Sex hormones 
menstrual cycle, vascular relaxation 163–168
Signal transduction 
G-proteins, adenylate cyclase 527–537*
Singapore 
genetic studies 264–266 
progress in clinical research 247–266
Skeletal muscle blood flow 
meal ingestion, insulin 415–423
Skin 
\(\alpha\)-adrenergic receptors, reflex sympathetic dystrophy 73–77
Skin fibroblasts 
intracellular pH, free cytosolic calcium 703–710
Skin microcirculation 
diabetic foot, neuropathy 559–565 
menstrual cycle 163–168
Sleep 
blood pressure, ambulatory monitoring 45–50
Smoking 
antioxidant enzyme, vitamin E 107–111
lymphocytes, cyclic AMP 621–626
Smooth muscle 
nitric oxide, alcoholic cirrhosis 23–28
Sodium absorption 
gallbladder, sodium/hydrogen exchanger 209–212
Sodium clearance 
renal transplant recipients, cyclosporin A 489–496
Sodium depletion 
frusemide 299–305
Sodium/hydrogen exchanger 
gallbladder, sodium absorption 209–212
Sodium pump 
hypokalaemic periodic muscle paralysis 261–264
Spectral power 
autonomic nervous system, heart failure 35–43
Spectrophotometry 
cardiac oxygenation, ischaemia 51–58
Spermatogenesis 
growth factors 254–256
Spine 
bone mineral density, postmenopausal women 307–312
Spiral laminar flow 
vascular disease, ultrasound 17–21
Splanchnic oxygen uptake 
amino acids, anaesthesia 431–439
Spontaneously hypertensive rats 
oxidative metabolism, brain 539–550
renal vasodilatation, angiotensin type 1 receptor antagonists 147–154
Stable isotope 
lymphocytes, protein synthesis 99–106
Stem cell production 
human embryos 248–249
Stomach 
chilli, capsaicin 252–254
Stroke 
cholesterol, lipids 399–413, 773–774
Stroke volume 
blood pressure, syncope 193–200
Subcellular fractionation 
muscle wasting, zymosan 475–481
Sudden death 
baroreflex sensitivity, insulin-dependent diabetes mellitus 59–64
Superoxide dismutase 
diabetes 441–448
Surgery
Subject Index

lymphocytes, protein synthesis 99–106
Sustained loading
  inspiratory effort sensation, CO₂ responsiveness 513–518
Sympathetic nervous system
  blood pressure, sleep 45–50
Syncope
  blood pressure, stroke volume 193–200
Syndrome X
  artery, morphology 739–743
T-cell receptor genes
  nasopharyngeal carcinoma 256–258
T-helper 2 cytokines
  blood transfusion 519–523
T-lymphocytes
  autoimmunity, biliary cirrhosis 551–558
Therapeutic targets
  potassium channel openers 651–663*
Thermogenesis
  amino acids, anaesthesia 431–439
Thermoregulation
  α-adrenoceptor antagonist 627–631
Thyroid hormones
  cardiac muscle, nutritional iron deficiency 233–239
Thyrotoxic periodic paralysis
  sodium pump 261–264
Tissue repair
  lung transplantation 319–327
Tolerance
  T-lymphocytes, biliary cirrhosis 551–558
Total body water
  chronic kidney failure 763–769
Total parenteral nutrition
  neutrophils, sepsis 371–374
Transforming growth factor
  blood transfusion 519–523
Triacylglycerol metabolism
  creatine supplementation 113–118
Tryptophan
  Na⁺, K⁺-ATPase, gestational hypertension 719–723
Tubular function
  renal transplant recipients, cyclosporin A 489–496
Tumour necrosis factor
  nutrients, inflammation 121–130*
  pentoxifylline, cirrhosis 29–33

Tumour suppressor gene
  nasopharyngeal carcinoma 256–258
Ultrasound
  blood flow, vascular disease 17–21
Urinary bladder
  calcium antagonist 467–474
Urinary state of saturation
  calcium nephrolithiasis, mineral water 313–318
Urogastrone
  cell proliferation, gastrointestinal tract 503–507
Vascular disease
  blood flow, ultrasound 17–21
  metabolism, amino acids 79–86
Vascular relaxation
  sex hormones, menstrual cycle 163–168
Vascular tone
  menstrual cycle 163–168
Vasoconstriction
  thermoregulation, α-adrenoceptor antagonist 627–631
Vasodilatation
  diabetes, dyslipidaemia 567–573
Vasodilator peptides
  adrenomedullin 3–16*, 525
Vasopressin
  contractile response, octreotide 601–606
Veins
  nitric oxide, alcoholic cirrhosis 23–28
Ventricular pacing
  natriuretic peptides, neutral endopeptidase 283–291
Vitamin E
  antioxidant enzyme, smoking 107–111
  inflammation, cytokines 121–130*
White-coat hypertension
  left ventricular function, echocardiography 275–281
Wine
  phenolic compounds, lipoprotein oxidation 449–458
X-ray absorptiometry
  chronic kidney failure 763–769
Zymosan
  muscle wasting, cytochrome c oxidase 475–481